A QbD World for Suppliers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A QbD World for Suppliers
The need for greater process understanding raises the bar for suppliers.


Pharmaceutical Technology
Volume 35, Issue 4, pp. 14


Patricia Van Arnum
After attending several events during the past few months, including conference sessions at Informex in Charlotte, North Carolina, in February, and the educational programs during DCAT Week, the week-long event of the Drug, Chemical, and Associated Technologies Association' (DCAT) in New York City in March, I observed the growing importance of FDA's quality-by- design (QbD) initiative in the pharmaceutical supply chain.

The QbD approach, which encourages a greater process understanding of a synthesis and related manufacturing for an active pharmaceutical ingredient (API), is not confined to the efforts of the large pharmaceutical companies. At the conferences that I attended, emerging pharmaceutical companies also spoke of the importance of QbD in a chemistry, manufacturing, and controls (CMC) package for APIs and finished drug products and of their interest in having a contract manufacturing organization (CMO) capable of developing a QbD-ready CMC process. Because many small pharmaceutical companies seek to partner with Big Pharma in their drug-development or commercialization efforts, making the CMC package acceptable to a potential large suitor, including incorporating QbD requirements, is important.

Large pharmaceutical companies also spoke of the need for CMOs and fine-chemical suppliers to share the process understanding in their manufacturing routes for the chemicals they supply, not just for finished APIs and advanced intermediates, but also for early-stage intermediates and starting materials. As the large pharmaceutical companies develop their regulatory filings with an QbD mindset, there is the growing expectation of suppliers to share deeper process information to facilitate those filings in a QbD-ready CMC environment.

Patricia Van Arnum is a senior editor of Pharmaceutical Technology.

Read Patricia's blogs at http://blog.PharmTech.com/.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here